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The FDA-approved anti-cancer 
drugs, streptozotocin and 
floxuridine, reduce the virulence of 
Staphylococcus aureus
Won-Sik Yeo1, Rekha Arya2, Kyeong Kyu Kim2, Hyunyoung Jeong3, Kyu Hong Cho4 & Taeok Bae1
In Staphylococcus aureus, an important Gram-positive human pathogen, the SaeRS two-component 
system is essential for the virulence and a good target for the development of anti-virulence drugs. In 
this study, we screened 12,200 small molecules for Sae inhibitors and identified two anti-cancer drugs, 
streptozotocin (STZ) and floxuridine (FU), as lead candidates for anti-virulence drug development against 
staphylococcal infections. As compared with STZ, FU was more efficient in repressing Sae-regulated 
promoters and protecting human neutrophils from S. aureus-mediated killing. FU inhibited S. aureus 
growth effectively whereas STZ did not. Intriguingly, RNA-seq analysis suggests that both compounds 
inhibit other virulence-regulatory systems such as Agr, ArlRS, and SarA more efficiently than they 
inhibit the Sae system. Both compounds induced prophages from S. aureus, indicating that they cause 
DNA damages. Surprisingly, a single administration of the drugs was sufficient to protect mice from 
staphylococcal intraperitoneal infection. Both compounds showed in vivo efficacy in a murine model of 
blood infection too. Finally, at the experimental dosage, neither compound showed any noticeable side 
effects on blood glucose level or blood cell counts. Based on these results, we concluded that STZ and FU 
are promising candidates for anti-virulence drug development against S. aureus infection.
The emergence of multi-drug resistant bacterial pathogens is a huge medical problem1. The problem is com-
pounded by the fact that the number of new antibiotics entering markets is decreasing2. Also, the growth inhi-
bition activity of antibiotics inevitably selects for resistant strains3,4. Therefore, to tackle the problem, along with 
the development of new class of antibiotics, we need to take a broad range of alternative approaches such as phage 
therapy and development of anti-quorum sensing drugs or anti-virulence drugs5,6.
S. aureus is a Gram-positive human pathogen colonizing skin, anterior nares and other mucosal surface and 
causes a variety of diseases ranging from skin and soft-tissue infections to life-threatening diseases such as endo-
carditis, toxic shock syndrome, and necrotizing pneumonia7,8. The success of S. aureus as a human pathogen is 
mainly due to the production of a large number of virulence factors. In S. aureus, the production of virulence 
factors is coordinately controlled by multiple regulators such as SarA, Agr, ArlRS, and the SaeRS two-component 
system (TCS)9–12. Of those, the SaeRS TCS is an excellent target for anti-virulence drug development13–15. 
Conserved in all clinical S. aureus strains, the SaeRS TCS controls the production of more than 20 important vir-
ulence factors including toxins (e.g., alpha-hemolysin, gamma hemolysin, and leukocidins), coagulases, adhesins, 
and enzymes (e.g., nucleases and proteases)12. More importantly, the SaeS’s kinase activity correlates with the bac-
terial virulence in mice16, suggesting that the SaeRS system is a viable target for the development of anti-virulence 
drugs against staphylococcal infections. Since no structural information is available for SaeS, however, a rational 
design of Sae inhibitors is not feasible yet.
In this study, by taking a high-throughput approach with a GFP-reporter system for the SaeRS TCS, we 
screened small molecule libraries for Sae-inhibitors and found that two anti-cancer drugs have excellent in vivo 
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efficacy in a murine model of staphylococcal infection. To understand their in vivo efficacy, we further studied the 
effect of the compounds on S. aureus.
Results
Screening small compound libraries for Sae inhibitors. With two SaeR binding sites, the P1 promoter 
of the sae operon is an excellent reporter for the Sae activity17 (Fig. 1a). The P1-gfp fusion was cloned in the mul-
ti-copy plasmid pYJ335, and the resulting plasmid pYJ-P1-gfp was inserted into S. aureus strain USA300, the 
predominant CA-MRSA (community associated-methicillin resistant S. aureus) in the USA18. Using the reporter 
strain, we screened 12,200 small compounds for Sae-inhibition activity and identified 85 compounds that sup-
press the GFP expression by more than 50% at 10 μM. Subsequently, all 85 compounds were studied in a murine 
model of intraperitoneal infection, and, out of the initial tests, 10 compounds showed in vivo efficacy to some 
extent. When the in vivo experiment was repeated for these 10 compounds, the following three FDA-approved 
anti-cancer drugs consistently showed statistically significant in vivo efficacy: streptozotocin (STZ), floxuridine 
(FU) and doxorubicin (Fig. 1b and c). The structures of the compounds are different from other reported TCS-
inhibitors19–22. Due to their excellent in vivo efficacy, STZ and FU were further studied.
Repression of the SaeRS system by STZ and FU. Along with the P1 promoter of the sae operon, the 
alpha-hemolysin promoter (Phla) is another well-characterized target of the SaeRS TCS17,23. In particular, the 
minimal Phla (Phlamin) has only the SaeR binding sites and the −35 and −10 promoter sequence of Phla. To compare 
their Sae-inhibitory activity, we measured IC50 (50% inhibitory concentration) of STZ and FU for P1 and Phlamin. 
As shown in Fig. 2, FU repressed the Sae-target promoters more efficiently than STZ did (0.5 μM vs. 13.5 μM for 
Figure 1. Identification of three anti-cancer agents with in vivo efficacy. (a) Overall procedure of the screening 
process. The number in parenthesis is the total number of compounds screened. The promoter sequences, 
−35 and −10, in the P1 promoter are indicated. SBS, the SaeR binding site. Parts of images were adapted 
from Motifolio Drawing Toolkits (www.motifolio.com). (b) Chemical structures and molecular weight of the 
identified compounds. (c) In vivo efficacy of the identified compounds. S. aureus (2 × 108 CFU) was i.p. injected 
into 18 mice. At 1 h post-infection, the corresponding compounds (100 μg, 5 mg/kg body weight) were i.p. 
injected once every day for 7 days. Statistical significance was assessed by Log-rank test. STZ, streptozotocin; 
FU, floxuridine.
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P1; 0.4 μM vs. 4.0 μM for Phlamin). Neither compound repressed the promoters of non-Sae-targets such as mecA 
and hrtB (Supplementary Fig. 1), indicating that the repression is target-specific.
Protection of neutrophils from S. aureus-mediated killing. Neutrophils are the most abundant white 
blood cells in human blood and critical for the defense against staphylococcal infection24. However, it is also well 
established that S. aureus can kill human neutrophils25. To understand the protective effect of STZ and FU on the 
host, we assessed whether the compounds could protect human neutrophils from killing by S. aureus. As with 
the Sae inhibition assay, FU protected human neutrophils from S. aureus-mediated killing much more efficiently 
than STZ did (IC50, 0.2 μM vs. 92.4 μM) (Fig. 3). Since STZ and FU showed similar in vivo efficacy (Fig. 1), these 
results might indicate that the neutrophil protection activity of a compound is not a good indicator for its in vivo 
efficacy. To examine this notion further, we measured IC50 for doxorubicin, which showed the least in vivo efficacy 
among them (Fig. 1). Again, doxorubicin protected human neutrophil more efficiently than STZ did (IC50, 4.2 μM 
vs. 92.4 μM) (Fig. 3), showing that the neutrophil-protection activity of a compound does not correlate well with 
its in vivo efficacy in a murine model of intraperitoneal infection.
Bacterial growth inhibition by STZ and FU. STZ and FU are known to have not only anti-cancer activ-
ity but also antibacterial activity26,27. Therefore, it is possible that the excellent in vivo efficacy of the compounds 
is due to their antibacterial activity. To examine this possibility, we determined the MIC (minimum inhibitory 
concentration) of the compounds using S. aureus USA300 in two different growth media: Mueller Hinton broth 
and tryptic soy broth. In the condition employed, STZ showed almost negligible antibacterial activity whereas 
Figure 2. Repression of the SaeRS system by the anti-cancer agents. S. aureus USA300 carrying either pYJ-P1-
gfp or pCL-Phlamin-gfp was grown to exponential growth phase in TSB; then a varying concentration of the anti-
cancer agents was added. At 3 h post-incubation, GFP expression was measured and normalized by OD600.
Figure 3. Protection of human neutrophils by the anti-cancer drugs. S. aureus USA300 (106 CFU) and human 
neutrophils (105 cells) were mixed, and the test compounds were added to the concentration indicated for 4 h. 
The viability of human neutrophils was measured by CellTiter assay (Promega). In the graph, the OD490 in the 
absence of compound was set to 100%.
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FU inhibited staphylococcal growth efficiently (Table 1). As compared with STZ, even doxorubicin showed more 
than 10 times higher activity of growth inhibition. Therefore, it is possible that the in vivo efficacy of FU might 
be, in part, due to its growth inhibitory activity, whereas the in vivo efficacy of STZ cannot be explained by its 
antibacterial activity.
Transcriptional alteration in S. aureus by STZ and FU. To understand the molecular basis of the in 
vivo efficacy of STZ and FU, we analyzed genome-wide transcriptional changes caused by the compounds. S. 
aureus USA300 at exponential growth phase was treated with 1 μg/mL (~4 μM) of either compound at 37 °C for 
3 h (Supplementary Fig. 2); then total RNA was purified and subjected to RNA-seq. Both STZ and FU caused 
significant transcriptional changes in S. aureus (STZ, 818 genes; FU 1180 genes, Fig. 4a, and Supplementary Table 
1–4). The majority of STZ-affected genes (76% up-regulated and 85% of down-regulated) were also similarly 
affected by FU, indicating that most anti-virulence mechanisms of STZ are shared by FU. At 4 μM, STZ is not 
expected to inhibit the SaeRS TCS (Fig. 2). Indeed, in the qRT-PCR analysis, STZ did not reduce the transcription 
of saeQ and saeS (Fig. 4b), although it did reduce the transcription of saeP. On the other hand, FU reduced the 
transcription of saeP and saeQ, but it increased the transcription of saeS (Fig. 4b). The molecular mechanism of 
the differential sae-repression is not clear. Intriguingly, both compounds appeared to inhibit the transcription of 
other virulence-regulatory systems such as Agr, ArlRS, and SarA more effectively than they inhibit the Sae system 
(Fig. 4b). The repression also appears to be specific because the transcription of the control gene gyrB and most 
other staphylococcal two-component systems including the SrrAB TCS was not significantly affected (gyrB and 
srrB in Fig. 4b and Supplementary Tables 1–4). Taken altogether, these data suggest that the highly effective in 
vivo efficacy of STZ and FU could be due to their repression of multiple regulatory systems.
Prophage induction by STZ and FU. Most clinical isolates of S. aureus carry prophages. Since induc-
tion of prophages kills the S. aureus host, it can be an effective antibacterial mechanism. The genome of the 
strain USA300 contains two prophages (ΦSa2usa and ΦSa3usa), of which ΦSa2usa is replication-defective28. The 
RNA-seq analysis showed that the treatment with the anti-cancer drugs increased the transcription of ΦSa3usa 
genes (Supplementary Tables S1 and S3), indicating induction of the prophage. To confirm the results, we grew 
S. aureus USA300 in TSB containing either STZ or FU (0.2 μg/mL) for 18 h and analyzed the culture supernatant 
by the soft-agar method. As shown, the culture supernatants produced a large number of plaques whereas the 
non-treated culture supernatant did not (Fig. 5), confirming the prophage induction by the compounds. These 
results also indicate that both compounds probably cause damages in the staphylococcal chromosome and that 
the prophage induction likely contributes to in vivo efficacy of the compounds.
Dose-dependent in vivo efficacy of STZ and FU. Next, we tested the dose-dependency of STZ and FU 
in their protective effect on the mice. A daily dose of 0.25 mg/kg (STZ) or 0.5 mg/kg (FU) was sufficient to show 
statistically significant protection against S. aureus infection (Fig. 6).
Effect of administration frequency on in vivo efficacy of STZ and FU. The biological half-life of 
STZ is 35–40 min29. The half-life of FU is also rather short (t1/2β = 2 h in human)30. Although in the previous 
experiments, the compounds were administered every day, due to their short half-lives, it is likely that S. aureus 
cells were exposed to the compounds for a brief period. Therefore, we hypothesized that a brief exposure to the 
compounds is sufficient to give significant in vivo efficacy. To examine the hypothesis, at 1 h post-infection with 
S. aureus, we administered the compounds only once (1.25 mg/kg body weight for STZ and FU; 2.5 mg/kg body 
weight for doxorubicin) and watched the infected mice for 7 days. As shown in Fig. 7, the single administration 
of the compounds showed in vivo efficacy similar to that of daily administration.
In vivo efficacy of STZ and FU in a murine model of blood infection. In our drug screening and 
subsequent animal studies, we used a murine model of intraperitoneal infection. However, the peritoneum is not 
a typical site of S. aureus infection. Therefore, STZ and FU were further tested in a murine model of blood infec-
tion, a common type of staphylococcal infections. S. aureus USA300 was administered into mice via retro-orbital 
injection; then, at 1 h post-infection, the compounds (2.5 mg/kg body weight) were injected into the mice via the 
intraperitoneal route. The drugs were administered once every day, and the mice were watched for 2 weeks. As 
shown in Fig. 8, both STZ and FU showed a statistically significant protective effect on murine survival whereas 
doxorubicin did not, confirming in vivo efficacy of STZ and FU in a clinically relevant animal model.
Effects of STZ and FU on murine blood glucose and bone marrow. At high doses, STZ is known to 
induce diabetes in rodents by killing β cells in the pancreas31,32. Besides, a high dose of 5-fluorouracil (5-FU), a 
metabolite of FU, is known to cause bone-marrow depression33. Therefore, we examined whether the dosage used 
in our animal experiment can cause those side effects. As expected, the 5-FU-treated mice showed a lower level of 
blood cell counts along with a sign of hypoglycemia, whereas the mice treated with either STZ or FU showed no 
Compounds Mueller Hinton Broth Tryptic Soy Broth
Streptozotocin >256 μg/mL (965 μM) >256 μg/mL (965 μM)
Floxuridine 0.0625 μg/mL (0.25 μM) 0.2 μg/mL (0.81 μM)
Doxorubicin 32 μg/mL (58.9 μM) 10 μg/mL (18.4 μM)
Table 1. MIC of the anti-cancer agents against S. aureus.
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such changes (Fig. 9). Even at 100 mg/kg, 20 times higher dose than the highest dose we used, STZ did not cause 
any significant changes in either blood glucose level or blood cell counts. These results indicate that both STZ and 
FU can reduce staphylococcal virulence at a safe dosage.
Discussion
In this study, through a small molecule screening with a reporter for the SaeRS TCS, we identified two anti-cancer 
drugs, STZ and FU, as attractive lead candidates for novel anti-virulence drugs against staphylococcal infections. 
For lead candidates, these two compounds have the following promising properties: (1) simple molecular struc-
ture with low molecular weight (Fig. 1); (2) excellent in vivo efficacy even at low dosage and with single adminis-
tration (Figs 1 and 6); (3) repression of multiple virulence regulators (Fig. 4); and (4) no overt adverse effect at the 
administration dosage (Fig. 9). In particular, with its excellent anti-growth and anti-virulence activities against 
Figure 4. The effect of streptozotocin (STZ) and floxuridine (FU) on the transcription in S. aureus USA300. 
(a) Summary of RNA-seq analysis. (b) Confirmation of the repression of other virulence regulatory systems by 
qRT-PCR. Y-axis indicates the mRNA level relative to that of gyrB, whose transcription was not significantly 
affected by the compounds. -, no treatment. Statistical significance was measured by unpaired, two-tailed 
Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
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Figure 5. Prophage induction by streptozotocin (STZ) and floxuridine (FU). NC, No compound.
Figure 6. Dose-dependent efficacy of streptozotocin (STZ) and floxuridine (FU). Mice (11–17 e.a.) were i.p. 
injected with S. aureus USA300 (2 × 108 CFU). At 1 h post-infection, a various amount of the compounds was 
i.p. injected. The compounds were administered once per day for 7 days. ns, not significant. The statistical 
significance was measured by Log-rank test.
Figure 7. Effect of single administration of the compounds on murine survival. Fifteen mice were used for 
streptozotocin (STZ, 50 μg) and floxuridine (FU, 50 μg) while ten mice were used for doxorubicin (50 μg). For a 
comparison purpose, the daily administration results were superimposed. Statistical significance was measured 
against the no compound control (black circle) by Log-rank test. ****p < 0.0001; *p < 0.05.
Figure 8. Efficacy of the anti-cancer drugs (50 μg) on staphylococcal blood infection. Ten mice were used for 
each condition. STZ, streptozotocin; FU, floxuridine; Dox, doxorubicin. Statistical significance was measured 
by Log-rank test against no drug control. ****p < 0.0001; *p < 0.05; ns, not significant. The survival difference 
between the STZ-treated mice and the FU-treated mice is not statistically significant (p = 0.105).
www.nature.com/scientificreports/
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S. aureus, FU has a potential to be developed into a dual agent, which inhibits not only the growth but also the 
virulence of S. aureus.
Although three compounds identified in the screening are all anti-cancer drugs, not all anti-cancer drugs have 
anti-staphylococcal activity. In the 12,200 small compounds screened in this study, 89 anti-cancer drugs were 
included. However, only three drugs, STZ, FU, and doxorubicin, repressed the Sae system and showed in vivo 
efficacy against S. aureus infection (Fig. 1c), suggesting that the anti-cancer activity itself is not sufficient to inhibit 
the SaeRS system and to protect the host from S. aureus-mediated killing. Intriguingly, of the 85 compounds 
showing anti-Sae activity in the initial screening (Fig. 1a), only three compounds showed significant in vivo activ-
ity, demonstrating that the in vitro Sae-inhibition activity does not guarantee in vivo efficacy of the compound. 
Since the sae-deletion mutant completely lost its virulence at the bacterial dosage used in the experiment16, these 
results imply that a partial repression of the Sae system is not sufficient to protect the host from staphylococcal 
infections. The repression of multiple regulatory systems (Fig. 4) and phage induction (Fig. 5) likely contribute to 
the in vivo efficacy of STZ and FU. Also, other pharmacological characteristics including in vivo half-life, plasma 
protein binding, and toxicity will also affect the overall in vivo efficacy of a compound. Therefore, in a drug devel-
opment process, it might be prudent to employ an in vivo efficacy assay at an early stage as possible.
Both STZ and FU are known to have antibacterial activity. In fact, STZ was initially identified as an antibi-
otic that inhibits the growth of both Gram-negative and Gram-positive bacteria including S. aureus26. In the 
original study, STZ was reported to inhibit S. aureus growth by 50% at 0.75 μg/mL26. FU was also reported to 
be a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313 μM)34. However, in our study, STZ 
showed a negligible anti-growth effect on S. aureus USA300 (Table 1). Although much more potent than STZ, the 
anti-growth effect of FU was about 10 times lower than that reported previously (Table 1). These discrepancies 
might be due to the differences in the test strain and the assay conditions employed. Interestingly, despite its low 
growth-inhibition activity, STZ showed a robust efficacy in vivo similar to that of FU (Figs 1, 6–8), signifying the 
importance of the anti-virulence activity of the compounds. Since 76–85% of the transcriptional effect of STZ are 
also observed in S. aureus treated with FU (Fig. 4), it is likely that most of the anti-virulence effects of STZ are 
also shared by FU.
Quinolone antibiotics such as ciprofloxacin are known to induce prophages via SOS-response35–38. Indeed, 
the 2 h-treatment of S. aureus 8325 with ciprofloxacin induced 16 prophage genes39. Analysis of non-prophage 
genes affected by STZ, FU, or ciprofloxacin showed that only a total of 22 genes (11 up-regulated, and 11 
down-regulated) were commonly regulated by the three compounds (Supplementary Fig. 3 and Supplementary 
Table 5), suggesting that the effect of ciprofloxacin on S. aureus is largely different from that of STZ or FU. Of the 
11 up-regulated genes, eight are involved in DNA repair, showing the induction of SOS-response is the primary 
effect shared by the three compounds. Intriguingly, along with alpha-hemolysin (hla), the virulence regulatory 
systems, Agr and SarA, were also commonly repressed by all three compounds. Although the molecular mech-
anism of the repression is not known, it is tempting to hypothesize that the induction of SOS-response gives 
negative impact on the virulence gene expression. Also, since STZ and FU appear to inhibit Agr more effectively 
than they inhibit the Sae system (Fig. 4b), it is possible that the repression of hla is through the repression of Agr, 
not the Sae system40.
As with cancer cells, bacteria can replicate indefinitely as long as a permissible growth condition is provided. 
Indeed, similarities between cancer cells and bacterial pathogens have been noted: high replication rates, damages 
to the host, spreading and dissemination within the host, and rapid development of resistance against therapeutic 
agents41. Even the immune response against bacterial pathogens has been used to treat certain types of tumor42–44. 
Although those similarities might be purely superficial without any biological connections, it is surprising to see 
that, of the 12,200 compounds screened, three compounds with in vivo efficacy are all anti-cancer agents. It is 
likely that the rapidly replicating nature of both types of cells makes them vulnerable to the anti-replication activ-
ity of the anti-cancer agents. Nonetheless, it remains to be seen whether there are other similarities between the 
pathogenic bacteria and cancer cells that can be targeted by the same therapeutic agent.
Figure 9. Effect of streptozotocin (STZ) and floxuridine (FU) on murine blood glucose and bone marrow 
depression. STZ and FU of the indicated amount were i.p. injected into three female mice. Seven days later, mice 
were sacrificed, and blood glucose concentration and blood cell counts were measured. PBS, phosphate buffered 
saline; 5-FU, 5′-fluorouracil. PBS and 5-FU were used as a negative and positive control, respectively. The 
normal blood glucose level was reported to be 153–171 mg/dL49. The normal values of cell counts are as follows: 
WBC, 3.2–12.7 (103/μL); Platelet, 0.766–1.657 (106/μL); Reticulocyte, 0.1258–0.469 (106/μL).
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Methods
Ethics Statement. The human subject experiment (i.e., purification of human neutrophils) was approved by 
the Indiana University Institutional Review Board (Study number: 1010002390). Before taking blood, informed 
written consent was obtained from each human subject. All experiments were performed in accordance with 
relevant guidelines and regulations. The animal protocol was approved by the Committee on the Ethics of Animal 
Experiments of the Indiana University School of Medicine-Northwest (Protocol Number: NW-43). The animal 
experiment was performed by following the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. Every effort was made to minimize the suffering of the animals.
Bacterial strains and growth conditions. The S. aureus strains and plasmids used in this study are 
described in Supplementary Tables 6. S. aureus was grown in tryptic soy broth (TSB). When necessary, antibiotics 
were added to the growth media at the following concentrations: erythromycin, 10 μg/mL; and chloramphenicol, 
5 μg/mL.
Construction of a GFP-promoter fusion. The reporter plasmids, pYJ-P1-g fp, pCL-Phlamin-g fp, 
pCL-PmecA-gfp, and pCL-PhrtB-gfp were generated by a ligation independent cloning method45. First, vectors were 
PCR-amplified from pYJ-gfp16 with the primers P1969/P1747 or from pCL55-gfp14 with the primers P1990/P1991 
(for pCL-Phlamin-gfp), P3016/P3017 (for pCL-PmecA-gfp), or P3286/P3287 (for pCL-PhrtB-gfp) (Supplementary 
Table 7). The insert DNA fragment containing the promoter sequence was amplified with primer pairs P1971/
P1972 for P1, P1992/P1993 (for Phlamin), P3014/P3015 (for PmecA), or P3284/P3285 (for PhrtB) (Supplementary 
Table 7). The PCR products were treated with T4 DNA polymerase in the presence of dCTP (vector) or dGTP 
(insert DNA) and mixed. DNA mixture was used to transform E. coli DH5α. Once verified, all plasmids were 
electroporated into S. aureus strain RN4220 and subsequently transduced into S. aureus strain USA300 with φ85.
High-throughput screening of small molecule libraries. S. aureus USA300 harboring pYJ-P1-gfp was 
used to screen 12,200 compounds (3,000 compounds from Spectrum Library [MicroSource Discovery Systems], 
6,000 from the discovery collection library [DCL, MicroSource Discovery Systems], and 3,200 natural com-
pounds [Indiana University]) in DMSO (stock concentration 10 mM). The compounds were dry transferred into 
384 plates using an Echo 550 Acoustic Liquid Transfer System. S. aureus USA300 (pYJ-P1-gfp) was grown in TSB 
overnight. The overnight culture was diluted 1:100 into fresh TSB and grown until OD600 = 0.5. Then 30 μL of the 
culture was transferred into the plate, resulting in 10 μM of the compounds. A negative control (DMSO blank) 
was included in each plate. Initial cell density and GFP fluorescence were measured after filling the plates. Plates 
were then sealed and incubated on a plate shaker-incubator at 37 °C for 3 h. The GFP signal (excitation 485 nm, 
emission 515 nm) and OD600 were measured with a Tecan Infinite M1000 Microplate Reader. The GFP signal was 
normalized by OD600, and the normalized value was used to identify the Sae inhibitor candidates.
Animal test. An overnight culture of S. aureus was 100-fold diluted into fresh TSB and further incubated 
at 37 °C for 4 h. Cells were collected by centrifugation, washed with sterile PBS, and suspended in sterile PBS 
to OD600 = 4 (i.e., 1 × 109 CFU mL−1). Sex-matched 8-week-old C57BL/6 mice were i.p. injected with S. aureus 
(2 × 108 CFU); then, at 1 h post-infection, a varying amount of compound was administered through i.p. injec-
tion. DMSO was used as a negative control. For daily dose experiment, the compound was i.p. injected every 24 h 
for seven days.
For retro-orbital studies for the compounds, the bacterial suspension (107 CFU in 100 μL) was administered 
into 10 sex-matched 8-week-old C57BL/6 mice via retro-orbital injection. At 1 h post-infection, test compounds 
(50 μg, 2.5 mg/kg) was administered by i.p. injection. The compounds were i.p. injected every 24 h for 14 days.
Statistical significance in murine survival was measured by Log-rank (Mantel-Cox) test with Prism 6 
(GraphPad).
Determination of MIC. Minimum inhibitory concentration (MIC) for streptozotocin, floxuridine, and dox-
orubicin was determined according to the recommendations proposed by the Clinical and Laboratory Standards 
Institute (CLSI) using microdilution method46.
RNA-seq analysis. An overnight culture of S. aureus in TSB was diluted 100 times in a fresh TSB (2 mL in a 
15 mL test tube) and incubated in a shaking incubator at 37 °C for 2 h. Then 1 μg/mL of streptozotocin or floxuri-
dine were added to the culture and further incubated for 3 h. After immediate stabilization of RNA in all samples 
by RNAprotect Bacteria Reagent (Qiagen), total RNA was isolated with RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s recommendations. For each condition, three RNA samples were isolated from three independ-
ent bacterial cultures. The isolated RNAs were sent to the Center for Genomics and Bioinformatics at Indiana 
University. Sequencing libraries were constructed using the ScriptSeq Complete Kit for Bacteria (Epicentre). The 
statistical analysis of the RNA-seq results was done with DeSeq. 2 as described before47.
qRT-PCR analysis. The total RNA used for RNA-seq was also used for qRT-PCR analysis. cDNA was synthe-
sized using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantification of transcripts 
was carried out by real-time PCR using SYBR Green PCR Master Mix (Applied Biosystems) in a QuantStudio 
7 Flex Real-Time PCR System (Applied Biosystems). Primers used to detect specific transcripts are shown in 
Supplementary Table 6. The relative amount of cDNA was determined using a standard curve obtained from PCR 
with serially diluted genomic DNA, and results were normalized to the levels of gyrB RNA. Statistical significance 
was measured by unpaired, two-tailed Student’s t-test with Prism 6 (GraphPad).
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GFP assay. An overnight culture of S. aureus harboring pYJ-P1-gfp, pCL-Phla min-gfp, pCL-PmecA-gfp, or 
pCL-PhrtB-gfp was diluted 100 times in a fresh TSB and incubated in a shaking incubator at 37 °C for 2 h. Then 
various concentrations of streptozotocin and floxuridine were added to cells, and the cells were incubated for 
3 h. The GFP signal (excitation 485 nm, emission 515 nm) and OD600 were measured with Enspire Plate Reader 
(Perkin Elmer). All GFP expressions were normalized by OD600. The half maximal inhibitory concentration 
(IC50) was calculated from at least three independent experiments via nonlinear regression analysis (sigmoidal 
dose-response with variable slope) using Prism 6 (GraphPad).
Neutrophil killing assay. Human neutrophils were purified from healthy adult blood donors by 
Ficoll-Paque gradient method48. The purified neutrophils were added to a 96-well tissue culture plate (2 × 105/
well) in 100 μL RPMI (Gibco) supplemented with 10 mM HEPES and 10% human serum. S. aureus cells 
(1 × 106 CFU) and various concentrations of streptozotocin, floxuridine, and doxorubicin were added to each 
well. Then, 10 μL of CellTiter 96® AQueous One Solution (Promega) was added to each well and incubated at 37 °C 
in 5% CO2 for 3–5 h. Neutrophil viability was assessed with the Enspire plate reader (Perkin Elmer).
Prophage induction by streptozotocin and floxuridine. S. aureus USA300 was grown in TSB con-
taining 0.2 μg/mL of the compounds (STZ or FU) or no compound (a negative control) at 37 °C for 18 h; then the 
supernatant was collected by filtration (0.22 μm). The supernatant (100 μL) was mixed with the overnight culture 
(100 μL) of S. aureus RN4220 suspended in HIB (heart infusion broth) containing 5 mM of CaCl2. The mixture 
was incubated at 37 °C for 10 min, mixed with soft TSA (0.8%), spread on TSA, and incubated at 37 °C for 18 h.
Blood glucose and bone marrow suppression tests in mice. Streptozotocin (0.1 mg [=5 mg/kg] and 
2 mg [=100 mg/kg]) and floxuridine (0.1 mg, 5 mg/kg) were i.p. injected into 8-week-old C57BL/6 mice. PBS and 
5-fluorouracil (5 mg, 250 mg/kg) were used a negative and positive control, respectively. Seven days later, mice 
were sacrificed, and blood was collected. The collected blood was sent to Biologic Resources Laboratory at the 
University of Illinois at Chicago, where blood cells were counted. Blood glucose concentration was measured by 
Contour blood glucose monitoring system (Asensia).
Accession number. The RNA-seq data were deposited in GEO (Gene Expression Omnibus) with the acces-
sion number GSE104069.
Data Availability. All processed RNA-seq results were included in Supplementary Tables 1–4. The raw data 
deposited to GEO (the accession number GSE104069) will be released on September 19, 2019.
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